Current status of agents active against the T315I chronic myeloid leukemia phenotype

Aine Carol Burke, Ronan T Swords, Kevin Kelly, Francis J. Giles

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction: T315I is a genetic mutation of the Bcr-Abl tyrosine kinase, the pathogenetic abnormality in chronic myeloid leukemia (CML). It accounts for 10 15% of clinically relevant CML mutations. Licensed tyrosine kinase inhibitors are ineffective against this mutation and its development reduces life expectancy of CML in chronic phase from 10 years to just 22 months. Extensive work is ongoing to establish the most effective therapy to overcome this mutation, including the development of novel specific agents and also re-examination of established therapies. Areas covered: This review examines the agents in development, dividing them into Bcr-Abl-dependant and -independent groups. It looks at the progress of this research, updating the reader on the status of agents previously reported and introducing emerging therapeutic possibilities only recently announced. Expert opinion: Development of the T315I mutation is a devastating event for some patients with CML. There are potential therapeutic agents at all stages of the drug development cycle to target this patient subpopulation. Clinical activity has been demonstrated and a number of agents are on the cusp of being licensed and available for use.

Original languageEnglish
Pages (from-to)85-103
Number of pages19
JournalExpert Opinion on Emerging Drugs
Volume16
Issue number1
DOIs
StatePublished - Mar 1 2011
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phenotype
Mutation
bcr-abl Fusion Proteins
Leukemia, Myeloid, Chronic Phase
Expert Testimony
Therapeutics
Life Expectancy
Protein-Tyrosine Kinases
Research
Pharmaceutical Preparations

Keywords

  • chronic myeloid leukemia
  • drug development
  • imatinib resistance
  • T315I

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Current status of agents active against the T315I chronic myeloid leukemia phenotype. / Burke, Aine Carol; Swords, Ronan T; Kelly, Kevin; Giles, Francis J.

In: Expert Opinion on Emerging Drugs, Vol. 16, No. 1, 01.03.2011, p. 85-103.

Research output: Contribution to journalArticle

Burke, Aine Carol ; Swords, Ronan T ; Kelly, Kevin ; Giles, Francis J. / Current status of agents active against the T315I chronic myeloid leukemia phenotype. In: Expert Opinion on Emerging Drugs. 2011 ; Vol. 16, No. 1. pp. 85-103.
@article{a0e5a8efa0e5451dbbc3c6a11b711129,
title = "Current status of agents active against the T315I chronic myeloid leukemia phenotype",
abstract = "Introduction: T315I is a genetic mutation of the Bcr-Abl tyrosine kinase, the pathogenetic abnormality in chronic myeloid leukemia (CML). It accounts for 10 15{\%} of clinically relevant CML mutations. Licensed tyrosine kinase inhibitors are ineffective against this mutation and its development reduces life expectancy of CML in chronic phase from 10 years to just 22 months. Extensive work is ongoing to establish the most effective therapy to overcome this mutation, including the development of novel specific agents and also re-examination of established therapies. Areas covered: This review examines the agents in development, dividing them into Bcr-Abl-dependant and -independent groups. It looks at the progress of this research, updating the reader on the status of agents previously reported and introducing emerging therapeutic possibilities only recently announced. Expert opinion: Development of the T315I mutation is a devastating event for some patients with CML. There are potential therapeutic agents at all stages of the drug development cycle to target this patient subpopulation. Clinical activity has been demonstrated and a number of agents are on the cusp of being licensed and available for use.",
keywords = "chronic myeloid leukemia, drug development, imatinib resistance, T315I",
author = "Burke, {Aine Carol} and Swords, {Ronan T} and Kevin Kelly and Giles, {Francis J.}",
year = "2011",
month = "3",
day = "1",
doi = "10.1517/14728214.2011.531698",
language = "English",
volume = "16",
pages = "85--103",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Current status of agents active against the T315I chronic myeloid leukemia phenotype

AU - Burke, Aine Carol

AU - Swords, Ronan T

AU - Kelly, Kevin

AU - Giles, Francis J.

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Introduction: T315I is a genetic mutation of the Bcr-Abl tyrosine kinase, the pathogenetic abnormality in chronic myeloid leukemia (CML). It accounts for 10 15% of clinically relevant CML mutations. Licensed tyrosine kinase inhibitors are ineffective against this mutation and its development reduces life expectancy of CML in chronic phase from 10 years to just 22 months. Extensive work is ongoing to establish the most effective therapy to overcome this mutation, including the development of novel specific agents and also re-examination of established therapies. Areas covered: This review examines the agents in development, dividing them into Bcr-Abl-dependant and -independent groups. It looks at the progress of this research, updating the reader on the status of agents previously reported and introducing emerging therapeutic possibilities only recently announced. Expert opinion: Development of the T315I mutation is a devastating event for some patients with CML. There are potential therapeutic agents at all stages of the drug development cycle to target this patient subpopulation. Clinical activity has been demonstrated and a number of agents are on the cusp of being licensed and available for use.

AB - Introduction: T315I is a genetic mutation of the Bcr-Abl tyrosine kinase, the pathogenetic abnormality in chronic myeloid leukemia (CML). It accounts for 10 15% of clinically relevant CML mutations. Licensed tyrosine kinase inhibitors are ineffective against this mutation and its development reduces life expectancy of CML in chronic phase from 10 years to just 22 months. Extensive work is ongoing to establish the most effective therapy to overcome this mutation, including the development of novel specific agents and also re-examination of established therapies. Areas covered: This review examines the agents in development, dividing them into Bcr-Abl-dependant and -independent groups. It looks at the progress of this research, updating the reader on the status of agents previously reported and introducing emerging therapeutic possibilities only recently announced. Expert opinion: Development of the T315I mutation is a devastating event for some patients with CML. There are potential therapeutic agents at all stages of the drug development cycle to target this patient subpopulation. Clinical activity has been demonstrated and a number of agents are on the cusp of being licensed and available for use.

KW - chronic myeloid leukemia

KW - drug development

KW - imatinib resistance

KW - T315I

UR - http://www.scopus.com/inward/record.url?scp=79952141077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952141077&partnerID=8YFLogxK

U2 - 10.1517/14728214.2011.531698

DO - 10.1517/14728214.2011.531698

M3 - Article

C2 - 21352071

AN - SCOPUS:79952141077

VL - 16

SP - 85

EP - 103

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 1

ER -